Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry
Open Access
- 5 October 2021
- Vol. 108 (2), 130-136
- https://doi.org/10.1136/heartjnl-2021-319552
Abstract
Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival. Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient. Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74±12 years vs 63±17 years, pConclusions APT during hospitalisation for COVID-19 could be associated with lower mortality risk and shorter duration of mechanical ventilation, without increased risk of bleeding. Trial registration number NCT04334291.Keywords
This publication has 33 references indexed in Scilit:
- Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With COVID-19Journal of the American College of Cardiology, 2020
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Platelet Activation and Aggregation Promote Lung Inflammation and Influenza Virus PathogenesisAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy.2005
- CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cellsNature, 1998
- Inhibition of NF-κB by Sodium Salicylate and AspirinScience, 1994